THERAPY DOSSIER · th-6b522c0427c6

Physalis alkekengi L. var. franchetii (PAF) extract

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32220053 ↗2020Reported benefit

Systems pharmacology reveals the mechanism of activity of Physalis alkekengi L. var. franchetii against lipopolysaccharide-induced acute lung injury.

MouseEndotoxin/LPSBALB/cMalen = 10 mice per group, four groups (control, LPS model, PAF 500…Oral gavage500 mg/kgPretreatment; LPS was injected 1 hour after the last PAF dose

Model: Acute lung injury induced by a single intraperitoneal injection of lipopolysaccharide (5 mg/kg)

PAF at 500 mg/kg reduced lung histopathological damage and the lung wet/dry ratio, lowered cytokine release including TNF-alpha and accumulation of oxidation products, decreased NF-kappaB, p-p38, ERK, JNK, p53, caspase-3 and COX-2, enhanced nuclear Nrf2 translocation, corrected the energy metabolis…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…